Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level
Journal of Translational Medicine volume 12, Article number: 328 (2014)
Glycated hemoglobin A1c (HbA1c) has been used as an index of glycemic control in the management, guidance, and clinical trials of diabetic patients for the past 35 years. The aim of this study was to validate the HbA1c model in patients with type 1 and type 2 diabetes and to use it to support interpretation of HbA1c in different clinical situations.
The HbA1c model was identified in 30 patients (15 with type 1 diabetes and 15 with type 2 diabetes) by estimating the overall glycation rate constant (k), based on results of continuous glucose monitoring. The model was validated by assessing its ability to predict HbA1c changes in cultures of erythrocytes in vitro and to reproduce results of the A1C-Derived Average Glucose (ADAG) study. The model was used to simulate the influence of different glucose profiles on HbA1c.
The mean k was equal to 1.296 ± 0.216 × 10−9 l mmol−1 s−1 with no difference between type 1 and type 2 diabetes. The mean coefficient of variation of k was equal to 16.7%. The model predicted HbA1c levels in vitro with a mean absolute difference less than 0.3% (3.3 mmol/mol). It reproduced the linear relationship of HbA1c and mean glucose levels established in the ADAG study. The simulation experiments demonstrated that during periods of unstable glycemic control, glycemic profiles with the same mean glucose might result in much different HbA1c levels.
Patients with type 1 and type 2 diabetes are characterized by the same mean value of k, but there is considerable interindividual variation in the relationship of HbA1c and mean glucose level. Results suggest that reciprocal changes in glycation rate and the life span of erythrocytes exist in a wide range of HbA1c values. Thus, for an average patient with diabetes, no modifications of parameters of the glycation model are required to obtain meaningful HbA1c predictions. Interpreting HbA1c as a measure of the mean glucose is fully justified only in the case of stable glycemia. The model and more frequent tests of HbA1c might be used to decrease ambiguity of interpreting HbA1c in terms of glycemic control.
Glycated hemoglobin A1c (HbA1c) has been used as an index of glycemic control in the management, clinical guidance, and clinical trials of diabetic patients for the past 35 years. In 2009, HbA1c became a diagnostic test for diabetes . In 2008, the multi-center A1C-Derived Average Glucose (ADAG) study was concluded, documenting the linear relationship between HbA1c and mean blood glucose (MBG) . For an average individual, this relationship can be used to report HbA1c as an estimated average glucose level over a period of 3 to 4 months (which is considered to be an approximate life span of erythrocytes) preceding HbA1c test execution. According to the ADAG study assumptions, such an estimate should fall within ±15% of the study-wide calculated level for 90% of the individual patients . However, this average linear relationship cannot be combined with any additional knowledge about the particular patient (e.g., results of HbA1c tests repeated within a short time period or information from a patient that she or he experienced a substantial improvement in glycemic control a few weeks ago) to narrow this 15% uncertainty range. Neither can it be used to study the influence of different glycemia profiles on the HbA1c level. For this purpose, mathematical modeling has been applied, among other methodologies -.
In 2011, Ladyzynski et al. demonstrated that it was feasible to approximate the average relationship of HbA1c and glycemia reported in the ADAG study using one of such models . The kinetics of hemoglobin glycation in this model can be characterized by an overall hemoglobin glycation rate constant (k). Besides the kinetics of the hemoglobin glycation reaction, the release of erythrocytes to the blood stream from the bone marrow and the elimination of erythrocytes from circulation were taken into account while calculating the average HbA1c level over all equal-aged cohorts of erythrocytes circulating in the vascular system at any given time.
Because the above-mentioned report  was based on data from healthy volunteers, it seemed advisable to validate the model using data from patients with diabetes. We expected the mean values of k to be similar in patients with type 1 and type 2 diabetes. However, we have not found any data in the literature confirming such an equality of the glycation rate constants in these two groups of patients. In reports available in the literature, the total number of cases studied so far in patients with diabetes is limited, making it difficult to draw conclusions about the mean values and the intersubject variability of k in type 1 and type 2 diabetes. Contrarily, many clinical studies reported high variability of HbA1c, which could hardly be explained by differences in glycemic control. Taking into consideration the different pathophysiology of type 1 and type 2 diabetes and considering all the factors other than glycemia that might influence the glycation rate (e.g., pH, oxidative stress, enzymatic deglycation, Schiff base inhibitors), the possibility that there are significant differences in formation of HbA1c in these two groups of patients cannot be ruled out.
The aim of the current work was threefold: (1) to estimate and compare the mean k and its interindividual variability in patients with type 1 and type 2 diabetes, (2) to validate the ability of the mathematical model to predict HbA1c concentration based on different glucose levels and to reproduce the relationship of HbA1c and glycemia established in the ADAG study, and (3) to simulate different glycemia profiles and their influence on the HbA1c concentration and to use these simulations to support interpretation of HbA1c in different clinical situations.
In the first part of the study, an experimental procedure described in detail elsewhere , was used to estimate k and to evaluate the HbA1c model. The procedure consisted of four phases, described below.
Blood glucose and HbA1c estimation in vivo
Glycemia course over a 120-day period was estimated based on CGM using a Guardian RT system (Medtronic Diabetes, Northridge, CA, USA) calibrated at least 4 times a day using capillary glucose measured with an Accu-Chek Go glucometer (Roche Diagnostics, Basel, Switzerland). Glucose concentrations measured with glucometers were rescaled to reflect the whole blood glucose concentrations as if they had been measured with the gold standard glucose analyzer YSI 2300 Stat Plus (Yellow Springs Instruments Inc., Yellow Springs, OH, USA) according to the linear regression reported by Cohen et al.. Then the results were multiplied by 1.11, as recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) , to reflect blood glucose (BG) concentrations in plasma. Based on the DirectNet study, it was assumed that Guardian RT neither underestimates nor overestimates glucose concentration in relation to the calibrating results . In each participant, 3 glucose sensors were applied for 6 days, with an assumed time span of 4 and 2 weeks between application of the first two and the last two sensors, respectively.
Two methods were used to estimate 120-day glycemia profiles. In the first method, we calculated two separate daily glycemia profiles representing working days and weekends by a point-wise averaging of the daily recordings (WW method). Then we connected these profiles repeatedly to obtain the extrapolated 120-day course. In the second method, the rescaled-to-plasma daily profiles were repeatedly copied to build the whole 120-day course, without any intermediate averaging (ID method). Both 120-day profiles were used to identify the individual k value for each subject and to evaluate the sensitivity of this estimate on the short-term glycemia variability. The k value was also calculated based on an analytical solution of the model under the assumption that BG was equal to the mean value (MBG) for 120 days.
The HbA1c was measured at the end of usage of the last sensor (5 repetitions were done) by applying the cation-exchange HPLC method with a D-10 analyzer (Bio-Rad Laboratories, Hercules, CA, USA). This analyzer measures HbA1c according to the National Glycohemoglobin Standardization Programme (NGSP) as a percentage of the total hemoglobin .
Cultivation of erythrocytes in vitro
At the end of glucose monitoring, 30 ml of blood was sampled for cultivation of erythrocytes. The erythrocytes isolated from the blood samples were cultured for up to 5 weeks at 37°C ,. Three glucose levels were maintained in culturing media corresponding to BG of 5.2 mmol/l, 10.5 mmol/l, and 15.7 mmol/l, respectively. Glucose concentrations measured in the medium using the YSI analyzer were divided by 1.06 to account for different water content in the plasma and in the medium .
The following procedure was used every day to sustain the presumed constant concentrations of glucose. First, a sample of the medium was taken to measure the glucose concentration before the old medium was replaced by the fresh one. Second, the hemolized erythrocytes were removed together with the old medium from a cell-culture dish, and then the fresh medium containing the desirable glucose concentration was added into the culture. The difference between the glucose concentration at the beginning and at the end of each day was decreasing with time because the number of viable erythrocytes that were able to metabolize glucose was also decreasing. Therefore, the glucose concentration in each culture was not constant but instead was changing, in a sawtooth-like manner, each day. To minimize errors that were made during HbA1c modeling, we interpolated these intraday changes of glucose concentration and used the interpolated values in the model.
A series of preliminary experiments with different glucose concentrations in the medium  confirmed that after 14 days of culturing, the molality of glucose in the medium and in the erythrocytes was the same (standard deviation of the absolute relative differences was equal to 3.6%). Glucose content in erythrocytes was not measured after the 14th day of culturing because of a limited volume of samples. Thus, it cannot be ruled out that glucose transport through the walls of the erythrocytes may be affected in vitro as a result of changes in the availability of GLUT1, which enable the facilitated diffusion of glucose. However, the influence of such changes on the results must have been limited in the current study because the constant levels of glucose were maintained in the medium.
We also sampled the cultures to measure HbA1c and to estimate the number of viable erythrocytes using Bürker’s chamber . Samples for HbA1c testing were frozen at −80°C until erythrocyte cultivation ended, and then HbA1c was assessed in all samples. To ensure the viability of erythrocytes in vitro (or our ability to properly remove nonviable cells and to detect viable cells), in the preliminary tests we used two methods in parallel to estimate the number of the viable cells in the cultures: a microscopic method with Bürker’s chamber and a cytometric method applying the Annexin V binding protocol. In the preliminary tests, described above , we conducted six in vitro experiments using blood samples from the healthy volunteers. The apoptotic cells were detected (in 5 samples in each experiment) using a FACSCalibur cytometer and CellQuest software (Becton Dickinson, San Diego, CA, USA).
We found a good agreement between the results of the cytometric and the microscopic analyses. The mean difference of the viable erythrocytes count expressed in relation to the erythrocytes’ count at the day of blood sampling for the in vitro experiments between the microscopic and the cytometric methods equaled 1.7 ± 2.8% (mean ± SD), p < 0.002 . This result confirmed that we were able to properly distinguish the apoptotic cells from the viable cells. Thus, we used the microscopic method in the main cycle of experiments.
Estimation of the overall glycation rate constant
The applied HbA1c model assumes that HbA1c level depends on three main processes: the kinetics of hemoglobin glycation, the release of the reticulocytes from bone marrow and the elimination of erythrocytes from circulation. The kinetics of hemoglobin glycation in the equal-aged cohort of erythrocytes was modeled with a simple differential equation :
where HbA denotes concentration of non-glycated hemoglobin and t is time.
The most important assumptions of the model are as follows: (1) the life span of erythrocytes is constant and equal to 120 days, (2) the turnover of erythrocytes is constant, (3) HbA1c concentration in the newly generated reticulocytes is equal to zero ,, (4) erythrocytes are eliminated in chronological order (“the oldest” ones are eliminated first) , and (5) the influence of the spleen-facilitated vesiculation on HbA1c is negligible ,. The influence of these assumptions on the modeled HbA1c was assessed earlier .
Based on these assumptions, a hemoglobin mass balance equation was utilized to calculate HbA1c level in the equal-aged cohort of erythrocytes at any particular point in time, depending on BG. These calculations were performed in parallel in 120 cohorts of erythrocytes of different ages (ranging from 1 day to 120 days), and then the results were averaged over all the cohorts to obtain the modeled HbA1c level that corresponds to the measured HbA1c level. To estimate a value of k, calculations were repeated with iteratively modified k until the absolute difference between the calculated and the measured HbA1c dropped below 0.046% (0.05 mmol/mol). To avoid overestimation of k, the calculations were performed using the unbiased IFCC-aligned HbA1c levels that were obtained from the NGSP-aligned ones according to the linear equation recommended by the IFCC . In this manuscript, HbA1c concentrations are reported according to both scales, with the NGSP-aligned values expressed in percentages of the total hemoglobin (%), followed by the IFCC-aligned values in millimoles of HbA1c per mol of the total hemoglobin (mmol/mol) given in parentheses.
The HbA1c model has been described in detail elsewhere and it has been proven to be capable of predicting HbA1c levels in nondiabetic individuals ,. In one of these reports , an analytical solution of the model was presented under an assumption of a constant glycemia throughout the entire life span of erythrocytes (HbA1c is NGSP-aligned and LS stands for the life span of erythrocytes in the equation below):
This equation was used to calculate values of k for all the study participants, based on their individual MBG values, and to compare them with values of k estimated numerically, based on extrapolated continuous glycemia courses obtained using the WW and ID methods.
The most important simplification of the model was related to the assumed constant life span of erythrocytes equal to 120 days. To show an influence of this assumption on the estimated values of k we also identified the model (i.e., estimated values of k for all the study participants) for alternative values of the life span equal to 60, 80, 100, 140 and 160 days.
Assessment of the model performance based on in vitro data
It was assumed that hemoglobin glycation obeys the same kinetics in vivo as it does in vitro. The models with k individualized for each subject were used to predict HbA1c changes assuming 4 different mechanisms of erythrocyte apoptosis during the in vitro cultivation: the chronological loss of cohorts, the uniform loss of erythrocytes from all cohorts, the combination of these two mechanisms, or the counter-chronological loss of erythrocytes (with the “youngest” erythrocytes being eliminated first). The percentage of the modeled erythrocytes that were left each day in the simulated cultures reflected the percentage of the viable erythrocytes measured in the real cultures. No new erythrocytes were added in the model to reflect the real-life conditions. A detailed description of the in vitro modeling was reported earlier ,. The mean difference (MD) and the mean absolute difference (MAD) of the measured and the predicted HbA1c levels were used to assess the model’s performance.
Modeling a relationship of HbA1c and blood glucose levels
In the second part of the study, the mean k and its intersubject variability were estimated for patients with type 1 and type 2 diabetes. The mean k was then used to model the linear relationship of HbA1c and MBG. The obtained linear function was compared with the experimental one that was reported in the ADAG study . However, the ADAG study reported a regression line with HbA1c as the independent variable, whereas the model-generated results should be compared with the line calculated with MBG as the independent variable (i.e., the one minimizing the prediction error of HbA1c based on MBG). In both cases, the correlation coefficient is the same but the slopes and intercepts of regression lines differ.
We had no access to the raw data from the ADAG population. Therefore, we used the published summary statistics of the ADAG study to build a statistical model of the ADAG population and to draw a sample of 10,000 pairs of HbA1c and MBG from this population with the Monte Carlo technique using the OpenBUGS 3.2.1 system . Based on these simulated data, a regression line of HbA1c vs. MBG was determined and compared with the relationship obtained using the HbA1c model.
In the third part of the study, the model with the mean k was used to simulate the influence of different 120-day-long glucose profiles on HbA1c, assuming a 120-day life span of erythrocytes. Additionally, the model with the mean k value was used to predict steady-state HbA1c concentrations for constant MBG values in case of shortening (to 60, 80, and 100 days) and lengthening (to 140 and 160 days) of the survival of erythrocytes.
The study group consisted of 30 sequentially enrolled non-Hispanic white adults including 15 patients with type 1 diabetes and 15 with type 2 diabetes. Exclusion criteria were proliferative retinopathy or maculopathy requiring treatment, renal impairment (creatinine higher than 177 μmol/l), heart failure (class III or IV, according to NYHA, or cardiac infarction within past 3 months), and mental impairment.
Baseline characteristics of the study group are presented in Table 1. All of the subjects had stable metabolic control prior to the enrollment and a regular lifestyle as confirmed by the results of an interview. The study adhered to the Declaration of Helsinki, the subjects provided informed written consent, and the local ethical committee approved the study protocol.
Normality of distribution of all variables was confirmed using the Shapiro-Wilk W test. Thus, the analysis of variance (ANOVA) or t-test was applied to analyze the data, using Statistica ver. 7.1 (StatSoft Inc., Tulsa, OK, USA). All results are presented as mean ± SD unless otherwise indicated. A p-value below 0.05 was considered statistically significant.
Mean value and interindividual variability of the overall glycation rate constant
Table 2 presents the results of in vivo monitoring of the metabolic control. The mean HbA1c was higher by 0.7% (7.4 mmol/mol) in patients with type 1 diabetes compared to those with type 2 diabetes (p = 0.07). This difference corresponded with a difference of MBG equal to 1.2 mmol/l (p = 0.02) and 1.3 mmol/l (p = 0.02), extrapolated using the WW and ID methods, respectively. The mean values of the resulting glycemia profiles were not different, regardless of the extrapolation method that was used. However, the mean standard deviation was higher when the ID method was used (p = 0.0000001, 0.000009, and 0.0000001 in patients with type 1 and type 2 diabetes and in the whole study group, respectively).
Table 3 shows a summary of statistics of values of k estimated individually for each study participant based on her or his 120-day-long glucose profile extrapolated using the WW and ID methods, as well as values of k calculated using an analytical solution of the model assuming a constant glycemia in the full 120-day period. In spite of differences in the glycemic variability, values of k estimated using both extrapolation methods and those calculated analytically were almost identical (p = 0.98), regardless of the type of diabetes (p = 0.82), as revealed by ANOVA. The k values calculated analytically based on the constant MBG were higher than those iterated using the WW glucose data in 25 out of 30 patients (p = 0.006). However, the mean relative absolute differences were as little as 0.7% ±0.6% and 1.3% ±1.2% and 1.0% ±1.0% in patients with type1 diabetes, patients with type 2 diabetes, and in the whole study group, respectively. In the case of k values estimated according to the WW and ID methods, these differences were equal to 0.7% ±1.0% and 1.7% ± 2.1% and 1.2% ±1.7%. Because of the absence of considerable differences in the average values of k estimated using three methods, the values of k estimated on the basis of the WW method are reported in the remaining part of this work.
Figure 1 demonstrates the mean values ± SD of k estimated for the life span of erythrocytes ranging from 60 to 160 days. This figure shows that the shorter life span of erythrocytes is assumed to be, the higher the glycation rate must be to adjust the model to the glucose and HbA1c measured in the study participants.
In spite of better metabolic control in patients with type 2 diabetes, the mean k values were identical in type 1 and type 2 patients (p = 0.96). The variance of k representing the intersubject variability was similar in both subgroups (p = 0.45). The coefficient of variation (CV) of k in patients with type 1 diabetes was equal to 16.7%, in those with type 2 diabetes, 17.2%; and in the whole study group, 16.7%.
Measured and predicted HbA1c concentration in vitro
Figures 2 and 3 present the measured HbA1c and mean courses of the predicted HbA1c during cultivation of the erythrocytes of patients with type 1 and type 2 diabetes, respectively. Figures 2 and 3 indicates that HbA1c is strongly overestimated when the assumption that erythrocytes are removed counter-chronologically is made.
Overestimation of the real HbA1c concentrations under this assumption can be explained in the following way. At the beginning of culturing of the erythrocytes, there is a mixture of erythrocytes in the culture aged from 0 to 119 days. The in vitro simulation starts with the calculated HbA1c levels existing in each equal-aged cohort of erythrocytes at the last day of the glucose monitoring in vivo. This means that the content of HbA1c in erythrocytes aged 0 days is almost zero while the content of HbA1c in erythrocytes aged 119 days is almost two times higher (in the case of a stable mean glycemia in vivo) than the average content, which is equal to the measured HbA1c.
During culturing of erythrocytes in vitro, there are two processes that can change the average HbA1c: hemoglobin glycation and the removal of nonviable erythrocytes. The first of these processes leads to an increase in the amount of the HbA1c in each viable erythrocyte remaining in the culture. If it were the only process, then the average HbA1c in vitro would always increase with time. However, the second process may lead to an increase, to stabilization, or to a decrease in the average HbA1c, depending on the way in which erythrocytes are eliminated from the culture. If erythrocytes are eliminated in the counter-chronological way, then, in general, the content of HbA1c in erythrocytes being removed is lower than the average content of HbA1c in erythrocytes remaining in the culture, which leads to an increase in the average HbA1c. Therefore, under the assumption of the counter-chronological removal of erythrocytes, both above-mentioned processes work together to increase the average HbA1c. This assumption seems to be the least realistic because it implies that the oldest erythrocytes can live in vitro longer than in vivo. That counter-chronological removal of erythrocytes is not realistic is confirmed by the fact that the simulated courses of HbA1c under this assumption are the most different from the real measured courses of HbA1c changes.
It is also noteworthy that differences between the simulated HbA1c concentrations on each particular day for cultures with different glucose concentrations in the case of the counter-chronological removal of the erythrocytes are similar (or even higher) than in the case of the measured differences. For example, in patients with type 1 diabetes, on the 14th day of culturing, differences for the simulated HbA1c concentration are equal to 0.61% between cultures containing 5.2 and 10.5 mmol/l of glucose, and are equal to 0.58% between cultures containing 10.5 and 15.7 mmol/l of glucose. In comparison, for the measured differences, the respective values are equal to 0.53% and 0.25%.
A chronological or uniform elimination of erythrocytes leads to more accurate predictions. The best predictions are obtained assuming the combined loss of erythrocytes containing chronological and uniform components (Table 4). In the whole study group, MDs were similar in cultures with different glucose concentrations (p = 0.29), whereas MADs tended to increase with an increase of glucose level in the culturing medium (p = 0.0000001). However, both indices were very small, demonstrating that the combined apoptosis made it possible to equalize the measured and the predicted mean HbA1c concentrations.
Linear relationship of HbA1c and MBG
The linear relationship of MBG as a function of HbA1c reported in the ADAG study was as follows :
We obtained almost the same parameters of the regression line using the simulated ADAG population:
This equation corresponds to the following relationship when MBG is considered the independent variable:
The relationship obtained using the model was as follows:
Figure 4 presents a comparison of the last two linear functions. The model overestimates HbA1c for the given MBG. However, the mean difference over all 10,000 simulated cases is as little as 0.23% ±0.05% (2.5 ± 0.5 mmol/mol). In the range of MBG from 4 to 20 mmol/l, the mean difference of HbA1c estimates is equal to 0.33% (3.6 mmol/mol).
Changes in HbA1c level in response to different simulated glycemic profiles
Figure 5A–C show simulations of different glycemia profiles and their influence on HbA1c level. Figure 5A presents HbA1c changes in response to the step improvement of the glycemia depending on the magnitude of improvement (6 hyperglycemia levels are simulated that drop to the normoglycemia of 5.6 mmol/l) and the duration of this improvement preceding HbA1c test execution. Similarly, Figure 5B shows HbA1c in response to the step deterioration of the glycemia. Based on these figures it can be observed, for example, that 60 days after a drop of BG from 22.2 mmol/l to 5.6 mmol/l, HbA1c is equal to 7.9% (62 mmol/mol), whereas 60 days after a rise in BG from 5.6 mmol/l to 22.2 mmol/l, HbA1c is equal to 12.5% (113 mmol/mol), despite the same average 120-day glycemia in both cases. Using Figure 5A, based on two HbA1c tests equal to 9.9% (85 mmol/mol) and 7.5% (58 mmol/mol) performed 30 days one after another and knowing that MBG was equal to 5.6 mmol/l in both cases, one can predict that the patient experienced a sudden drop of glycemia from 19.4 mmol/l about 30 days before the first HbA1c test was executed.
Figure 5C illustrates the reaction of HbA1c to the temporal (rectangular shape) deterioration of BG lasting for 30 days, depending on the magnitude of this deterioration and a time period between the end of the hyperglycemia and execution of the HbA1c test. For example, in the case of the glycemia deterioration from 5.6 to 22.2 mmol/l lasting for 30 days, HbA1c varies from 9.7% (82.6 mmol/mol) to 6.1% (43.3 mmol/mol), depending on the time span between the end of the hyperglycemia and the day of HbA1c test execution.
Figure 6 demonstrates changes of HbA1c in response to the ramp improvement and the ramp deterioration of the glycemia lasting for 120 days, depending on the slope of the ramp. For example, for the linear improvement of the glycemia from 22.2 mmol/l to 5.6 mmol/l, HbA1c concentration is equal to 8.7% (71 mmol/mol) and for the deterioration – it is equal to 11.8% (105 mmol/mol). The MBG concentration is the same in both cases, as it was in the examples illustrated in Figures 5A and B.
It should be mentioned that if we assumed an erythrocyte life span different than 120 days, then the HbA1c courses presented in Figures 5A-C would have the same shapes but the time scale would be different. For example, for a life span of 100 days, a new steady-state HbA1c after a step improvement or deterioration of the glycemia would be achieved after 100 days, not 120 days.
Figure 7 illustrates an effect of shortening or lengthening of the life span of erythrocytes on HbA1c in a patient having the glycation rate constant equal to the mean value estimated in 30 study participants for the life span of 120 days. Such a shortened life span occurs, for example, in hemolytic or sickle cell anemia and the lengthened life span can be observed in thalassemia.
The last simulation assessed whether HbA1c concentration was a sensitive indicator of hypoglycemia or, in general, of short-term glucose variability. For this purpose two daily glucose profiles were prepared using AIDA , a model-based online simulator of a patient with type 1 diabetes. One of these profiles includes an episode of severe hypoglycemia (Figure 8A). Both profiles were applied to compose 120-day glycemia courses with variable frequency of the daily hypoglycemic profiles (from “none” to “everyday”), which were used to model HbA1c. As shown Figure 8B, for a patient with a mean value of k, HbA1c is equal to 6.4% (46 mmol/mol) when no hypoglycemia occurs, and it is equal to 5.8% (40 mmol/mol) when hypoglycemia episodes occur every day. We calculated that there is still a 29% chance that the HbA1c level is higher in a patient experiencing hypoglycemia every day than in a patient who does not experience hypoglycemia at all, because of the intersubject variability of the hemoglobin glycation rate.
The mean overall glycation rate constant values identified using 120-day glycemia courses that were extrapolated based on the CGM data in patients with type 1 and type 2 diabetes support the notion of the same mean rate of hemoglobin glycation in these two groups of diabetic patients. The mean k reported in this study is just 3.1% higher than the mean k obtained in 10 healthy volunteers, estimated earlier using the same methodology , and 2.0% higher than the one that we calculated based on the results of the 3-month CGM data for 22 patients with diabetes and for 3 nondiabetic subjects presented by Nathan et al.. The mean k reported here is also in a good agreement with previously reported values estimated on the basis of a limited number of samples utilizing in vivo or in vitro experiments, when methodological differences are accounted for ,,,,.
The mean k values were only marginally different for three methods of the long-term glycemia extrapolation that were used. This result confirms the data reported in the clinical studies showing that HbA1c is sensitive to MBG level but not to glycemic short-term variations ,- because the MBG levels used in these three methods were very similar to each other, whereas the glucose variability measures were significantly different.
The life span of erythrocytes shorter or longer than the assumed 120-day would not change the conclusion that the mean k is similar in patients with type 1 and type 2 diabetes, provided that the mean erythrocyte survival was similar in these two groups. However, the mean value of k would be affected if the erythrocyte life span was different than 120 days.
The interindividual CV of k was similar regardless of the type of diabetes, but it was higher than the value reported earlier in healthy volunteers  (p = 0.025). The obtained CV is high, but it cannot be automatically attributed in full to variability of glycation rate. Ladyzynski et al. demonstrated that a major part of variability of k in healthy volunteers could be explained by random errors of HbA1c and glycemia measurements and, more importantly, by a heterogeneity of erythrocyte life span .
Furne et al.  estimated that by using the end-alveolar carbon monoxide technique, the standard deviation of the life span of erythrocytes in healthy subjects was equal to 23 days. This value is more than enough to explain the variability of k obtained in the current study and to justify the resulting differences in HbA1c corresponding to a given glucose concentration, which can be observed in Figure 4, where, for example, at an MBG equal to 15.5 mmol/l, HbA1c varies from 8.3% (68 mmol/mol) to 13.8% (127 mmol/mol). Higher CV of k noted in our study in comparison with the study concerning healthy volunteers  suggests that the heterogeneity of the life span of the erythrocytes might be higher in patients with diabetes. This is in line with the results reported by Virtue et al., who demonstrated that in a group of patients with type 2 diabetes, this parameter was equal to 25 days.
Higher CV noted in our study suggests that the other above-mentioned sources of variability might also be more pronounced or that k is more significantly influenced by other factors (e.g., oxidative stress ) in patients with diabetes than in healthy subjects. Further studies are required to confirm this hypothesis. Nevertheless, the model also can be individualized, applying the method used in this study, to fit a particular patient’s data more precisely.
The HbA1c model with k individually identified for each patient was used to predict HbA1c in cultures of patients’ erythrocytes. We tested a few possible modes of erythrocyte removal, because of a lack of any method that could actually measure which erythrocytes are lost. The results indicated a high ability of the model to predict HbA1c when two modes of erythrocyte removal – chronological loss and uniform loss – were combined. The results of in vitro studies strengthen the validity of the model under in vivo conditions, because both models share the same k for a particular subject and the in vitro simulation starts with the calculated HbA1c levels in each equal-aged cohort of erythrocytes on the last day of the glucose monitoring in vivo. This means that the two models are strongly interrelated .
The average linear relationship of HbA1c as a function of MBG, which was modeled using the mean k and a constant 120-day life span of erythrocytes, reproduced the relationship of these variables obtained using the data sampled from the ADAG population despite differences between the groups (e.g., in terms of ethnicity, proportion of nondiabetic individuals and patients with type 1 and type 2 diabetes). This is yet another confirmation of the validity of the model.
More importantly, the fact that both linear relationships are almost identical has significant implications regarding the glycation rate, the life span of erythrocytes, and the glycemic control. On the one hand, if the life span of erythrocytes shortens with a worsening of glycemic control, as was suggested in a few reports ,, then the mean k must increase to compensate for the shorter time of glycation (otherwise the slopes of both lines would have to be different). Possible mechanisms responsible for such an increase include patients’ susceptibility to oxidative stress and an association of hyperglycemia with free-radical-mediated lipid peroxidation  or the existence of high and low hemoglobin glycation phenotypes ,. On the other hand, some studies have indicated that the life span of erythrocytes is independent of glycemic control or even that it is longer in patients with poorer control ,,, implying that the mean glycation rate is not correlated or that it is negatively correlated with glycemic control.
Unfortunately, based solely on the hemoglobin glycation model, it is not possible to judge, whether the life span of erythrocytes and the glycation rate constant are negatively, positively, or not correlated with HbA1c. This is related to the fact that in the model the glycation rate constant k and the life span of erythrocytes are not present separately but as a product of these two variables (see, above, the second equation in section Estimation of the overall glycation rate constant). Therefore, it is not possible to reach a conclusion about possible changes of one of these parameters as a function of HbA1c without having prior knowledge about changes of the other parameter. A reliable method of measuring the survival of erythrocytes in vivo is required to solve this problem. In the absence of such a method, mathematical modeling can be used to incorporate a description of the aging of erythrocytes into the glycation model .
From a practical point of view, the most important conclusion, that can be drawn from a good agreement of both linear relationships considered above, is that changes in the life span must be balanced by changes in the glycation rate across the wide range of HbA1c levels to ensure nearly a constant product of these two variables; otherwise it would not be possible to reproduce the average relationship of HbA1c and MBG obtained in the ADAG study using the model with k equal to 1.296 × 10−9 l mmol−1 s−1 and the 120-day life span of erythrocytes. In fact, the same result would be achieved even if some other value of the life span of erythrocytes were assumed. This is related to the fact that k is estimated from the model based on the assumed life span of erythrocytes, that is, the shorter the life span, the higher the estimated value of k and vice versa.
Because of a good agreement of the simulated and the experimental relationship of HbA1c and MBG obtained using the mean k and the same mean life span of erythrocytes, the same values of these parameters can be used to obtain reliable predictions of HbA1c in response to different glycemic profiles in the average patient with diabetes. We conducted a few series of such predictions for different glycemic profiles preceding the HbA1c test execution. The conclusions from these predictions are as follows: (1) interpreting HbA1c as a measure of MBG is meaningful only in the case of stable glycemic control; (2) the HbA1c level might vary widely during sudden changes in glycemia, even in the case of glycemia profiles with the same MBG level; (3) HbA1c is not a sensitive indicator of short-term glycemic variability; and (4) there is a considerable ambiguity in interpreting the result of a single HbA1c measurement when no additional information about the patient is available (e.g., previous HbA1c or BG values).
These conclusions are in good agreement with observations known from clinical practice and demonstrated in clinical trials. However, using the model it is possible to assess what quantitative statements (for example, “HbA1c is not a sensitive indicator of the short-term glycemic variability”) really mean in terms of concrete numerical values of HbA1c and BG.
From a practical standpoint, the most important value of the presented work is that having a positively verified model, in which k can be identified for a particular patient, and taking into consideration the relative mathematical simplicity of the model, more frequent tests of HbA1c might be used together with the results of modeling to decrease ambiguity of interpreting HbA1c in terms of glycemic control. For example, one can calculate monthly estimates of MBG using the model and monthly HbA1c tests instead of assuming that BG was constant for the whole life span of erythrocytes. In other words, the model make it possible to improve interpretability of the most recent HbA1c value by combining all the evidence available within 3–4 months related to glycemia monitoring and HbA1c testing.
Our results support the notion that patients with type 1 and type 2 diabetes are characterized by the same mean value of the overall glycation rate constant. There is no significant difference between the mean value of this parameter in patients with diabetes and in healthy individuals.
The obtained results suggest that reciprocal changes in glycation rate and the life span of erythrocytes exist in a wide range of HbA1c values. Thus, for an average patient with either type 1 or type 2 diabetes, no modifications of parameters of the hemoglobin glycation model are required to obtain meaningful HbA1c predictions. Such a model can be used to simulate the influence of different glycemia courses on HbA1c level, making it possible to go beyond the averaged linear relationship of HbA1c and the mean glucose level over the whole life span of erythrocytes. Simulation experiments that were conducted confirm observations known from the clinical practice (i.e., that interpretation of HbA1c as a measure of MBG is fully justified only in the case of the stable glycemic control and that HbA1c is not a sensitive indicator of short-term glycemic variability).
There is considerable intersubject variation in the relationship of HbA1c and the mean blood glucose level. Based on evidence from the literature, the variation is more likely related to the heterogeneity of the life span of erythrocytes than to variability of the glycation rate constant, but further studies are required to confirm this hypothesis. Nevertheless, the model can be individualized to fit a particular subject’s data by applying the method used in our study. The model and more frequent tests of HbA1c might be used to decrease ambiguity of interpreting HbA1c in terms of glycemic control.
A1C-Derived Average Glucose Study
Blood glucose concentration
Continuous glucose monitoring
Coefficient of variation
- HbA1c :
Glycated hemoglobin A1c
Method of extrapolating 120-day glycemia course based on the continuous glucose monitoring data without averaging
International Federation of Clinical Chemistry and Laboratory Medicine
- k :
Overall hemoglobin glycation rate constant
Life span of erythrocytes
Mean absolute difference (of the measured and the modelled HbA1c levels)
Mean blood glucose concentration
Mean difference (of the measured and the modelled HbA1c levels)
National Glycohemoglobin Standardization Programme
Method of extrapolating 120-day glycemia course based on two mean daily glucose profiles representing working days and weekends
Nathan DM, The International Expert Committee: International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009, 32: 1327-1334. 10.2337/dc08-9025.
Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ: Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008, 31: 1473-1478. 10.2337/dc08-0545.
Beach KW: A theoretical model to predict the behavior of glycosylated hemoglobin levels. J Theor Biol. 1979, 81: 547-561. 10.1016/0022-5193(79)90052-3.
Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM: The biosynthesis of human hemoglobin A1c. Slow glycation of hemoglobin in vivo. J Clin Invest. 1976, 57: 1652-1659. 10.1172/JCI108436.
Graf RJ, Halter JB, Porte D: Glycosylated hemoglobin in normal subjects and subjects with maturityonset diabetes. Evidence for a saturable system in man. Diabetes. 1978, 27: 834-839. 10.2337/diab.27.8.834.
Higgins PJ, Bunn HF: Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem. 1981, 256: 5204-5208.
Ladyzynski P, Wojcicki JM, Bak M, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Validation of hemoglobin glycation models using glycemia monitoring in vivo and culturing of erythrocytes in vitro. Ann Biomed Eng. 2008, 36: 1188-1202. 10.1007/s10439-008-9508-x.
Mortensen HB, Christophersen C: Glucosylation of human haemoglobin A in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta. 1983, 134: 317-326. 10.1016/0009-8981(83)90370-4.
Kovatchev BP, Flacke F, Sieber J, Breton MD: Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose data. Diabetes Technol Ther. 2014, 16: 303-309. 10.1089/dia.2013.0224.
Osterman-Golkar SM, Vesper HW: Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complicat. 2006, 20: 285-294. 10.1016/j.jdiacomp.2005.07.009.
Tahara Y, Shima K: The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care. 1993, 16: 1313-1314. 10.2337/diacare.16.9.1313.
Ladyzynski P, Wojcicki JM, Bak MI, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W: Hemoglobin glycation rate constant in non-diabetic individuals. Ann Biomed Eng. 2011, 39: 2721-2734. 10.1007/s10439-011-0366-6.
Cohen M, Boyle E, Delaney C, Shaw J: A comparison of blood glucose meters in Australia. Diabetes Res Clin Pract. 2006, 71: 113-118. 10.1016/j.diabres.2005.05.013.
D’Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, Larsson L, Lewenstam A, Maas AHJ, Mager G, Naskalski JW, Okorodudu AO, International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT): Approved IFCC recommendation on reporting results for blood glucose. Clin Chem Lab Med. 2006, 44: 1486-1490.
The Diabetes Research in Children Network (DirectNet) Study Group: The accuracy of the Guardian® RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technol Ther. 2008, 10: 266-272. 10.1089/dia.2007.0279.
Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM, IFCC Working Group on HbA1c Standardization: IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004, 50: 166-174. 10.1373/clinchem.2003.024802.
Zhang Y, Neelamegham S: Cell counter, blood. Encyclopedia of Medical Devices and Instrumentation. Edited by: Webster JG. 2006, John Wiley & Sons, New York, 81-90.
Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood. 2008, 112: 4284-4291. 10.1182/blood-2008-04-154112.
Lunn D, Spiegelhalter D, Thomas A, Best N: The BUGS project: evolution, critique and future directions (with discussion). Stat Med. 2009, 28: 3049-3082. 10.1002/sim.3680.
Lehmann ED, Deutsch T, Carson ER, Sonksen PH: AIDA: an interactive diabetes advisor. Comput Meth Programs Biomed. 1994, 41: 183-203. 10.1016/0169-2607(94)90054-X.
Nathan DM, Turgeon H, Regan S: Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007, 50: 2239-2244. 10.1007/s00125-007-0803-0.
Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR, on behalf of the ADAG Study Group: Associations between features of glucose exposure and A1C. The A1C-Derived Average Glucose (ADAG) Study. Diabetes. 2010, 59: 1585-1590. 10.2337/db09-1774.
McCarter RJ, Hempe JM, Chalew SA: Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability. An analysis of data from the Diabetes Control and Complications Trial. Diabetes Care. 2006, 9: 352-355. 10.2337/diacare.29.02.06.dc05-1594.
Furne JK, Springfield JR, Ho SB, Levitt MD: Simplification of the end-alveolar carbon monoxide technique to assess erythrocyte survival. J Lab Clin Med. 2003, 142: 2-57. 10.1016/S0022-2143(03)00086-6.
Virtue MA, Furne JK, Nuttall FQ, Levitt MD: Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004, 27: 931-935. 10.2337/diacare.27.4.931.
Selvaraj N, Bobby Z, Sathiyapriya V: Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin Chim Acta. 2006, 366: 190-195. 10.1016/j.cca.2005.10.002.
Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML: Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med. 1977, 86: 425-429. 10.7326/0003-4819-86-4-425.
Hempe JM, Gomez R, McCarter RJ, Chalew SA: High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002, 16: 313-320. 10.1016/S1056-8727(01)00227-6.
Gould BJ, Davie SJ, Yudkin SJ: Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997, 260: 49-64. 10.1016/S0009-8981(96)06508-4.
Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984, 310: 341-346. 10.1056/NEJM198402093100602.
Sayinalp S, Sozen T, Usman A, Dundar S: Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life. J Diabetes Complicat. 1995, 9: 190-193. 10.1016/1056-8727(94)00041-L.
Lledó-García R, Mazer NA, Karlsson MO: A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn. 2013, 40: 129-142. 10.1007/s10928-012-9289-6.
This study was supported by a research grant from the National Centre for Science (Grant no. N N518 289340). Authors would like to extend their sincere appreciation to Professor Jan M. Wojcicki from the Nalecz Institute of Biocybernetics and Biomedical Engineering PAS, who passed away unexpectedly on December 28th, 2013, for his contribution to design of this study, the data analysis and interpretation.
The authors declare that they have no competing interests.
PL conceived and designed the study, analyzed and interpreted the data and wrote the manuscript. PF acquired the data, performed the statistical analysis and wrote the manuscript. MIB designed the study and interpreted the data. SS acquired and analyzed the data. JKr interpreted the data and made critical revisions of the manuscript for important intellectual content. JKa researched the data and reviewed the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Ladyzynski, P., Foltynski, P., Bak, M.I. et al. Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level. J Transl Med 12, 328 (2014). https://doi.org/10.1186/s12967-014-0328-5
- Diabetes mellitus
- Glycated hemoglobin A1c
- Diabetes management
- Glycemic control
- Chronic glycemia
- Continuous glucose monitoring
- Cultivation of erythrocytes in vitro